Next-Generation Orthopoxvirus Inhibitors

About SIGA Technologies

SIGA Technologies is a biopharmaceutical company with a specialized mission to address health security threats, particularly biological, chemical, radiological, and nuclear (CBRN) agents. Its primary achievement is the development and regulatory approval of TPOXX, the first and only FDA-approved drug for smallpox, supported by substantial procurement contracts from the U.S. government's Strategic National Stockpile. The company's strategic direction involves leveraging its antiviral expertise to expand its pipeline for other high-consequence pathogens and to pursue international sales of its approved product. Its financial position is strengthened by recurring government contracts, providing a stable revenue base.

Therapeutic Areas